Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4)
Cytotoxic T-lymphocyte associated protein 4 (CTLA-4), encoded by the CTLA4 gene, is a transmembrane glycoprotein receptor stored predominantly intracellularly and transiently transported to the cell surface after T-cell activation in activated T cells and regulatory T cells (Tregs).
Cytotoxic T-lymphocyte associated protein 4 (CTLA-4), encoded by the CTLA4 gene, is a transmembrane glycoprotein receptor stored predominantly intracellularly and transiently transported to the cell surface after T-cell activation in activated T cells and regulatory T cells (Tregs). It functions as a critical negative regulator of T cell-mediated immune responses, acting as an inhibitory checkpoint that restrains excessive immune activation and maintains peripheral self-tolerance. CTLA-4 competes with the co-stimulatory receptor CD28 for binding to B7 ligands (CD80 and CD86) on antigen-presenting cells such as dendritic cells, but with far greater affinity, enabling it to outcompete CD28 and dampen T cell activation signals. This competitive inhibition is central to immune homeostasis: CTLA-4 signaling limits the proliferation and effector function of cytotoxic T cells while reinforcing the suppressive activity of regulatory T cells, thereby preventing autoimmunity.
The biological significance of CTLA-4 extends beyond immune tolerance to encompass a central role in tumor immune evasion. Because tumors can exploit CTLA-4-mediated suppression to escape immune surveillance, blocking this checkpoint has become a cornerstone of cancer immunotherapy. The anti-CTLA-4 monoclonal antibody ipilimumab was the first immune checkpoint inhibitor approved by regulatory agencies, establishing proof-of-concept for the broader class of checkpoint inhibitor therapies. CTLA-4 acts in close functional concert with other inhibitory receptors including PD-1, LAG3, TIM-3, and TIGIT, and its interplay with the PD-1/PD-L1 pathway has become a major axis of contemporary immuno-oncology research.
Where the papers sit
19 papers from the last 6 months study Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) directly · updated from PubMed 7 Oct 2026
Study type 1 clinical trial · 2 observational · 5 human data · 11 preclinical
Themes 4 themes · 1 paradigm shift · 1 new direction
-
Checkpoint Autoimmunity and Cancer
Checkpoint therapy is being shaped around the trade-off between antitumor immunity and loss of immune tolerance. Myasthenia gravis and myocarditis illustrate severe immune-related adverse events, while rogue regulatory T cells and TREX1 loss point to mechanisms of dysregulation. Engineering anti-CTLA-4 agents and profiling cytokines, chemokines and IL16 aim to improve efficacy and identify risk. Clinical work includes PD-1/PD-L1 and CTLA-4 blockade in cervical and head and neck cancers.
6 papers · 31.6%
-
T-Cell-Directed Cancer Immunotherapy
Combination immunotherapy is moving toward deliberate expansion and selection of tumor-reactive CD8+ T-cell clones. Lymphodepleting chemotherapy, in situ vaccination, radionuclide therapy and oncolytic virus treatment are paired with checkpoint blockade, including anti-CTLA-4 enhancement of IL-18R1+ cells. Transcriptomic, circulating miRNA and IL-2/Treg analyses seek biomarkers of response, including in microsatellite-stable colorectal and breast cancers. The main open question is how to convert these immune expansions into durable survival gains.
6 papers · 31.6%
-
Checkpoint Immune Regulation
Checkpoint biology is being extended from cancer response prediction to direct control of immune activation in tumors and infection. Gut microbiome and gene signatures are being developed as cross-cancer biomarkers, while ethoxzolamide promotes β-TrCP-dependent PD-L1 ubiquitination. IFNG-linked effector CD4 T-cell programs and CTLA-4 regulation recur as determinants of immune state. The cryptococcosis work broadens the subject by showing that paradoxical Th1 activation can aid latent infection control rather than simply drive pathology.
4 papers · 21.1%
-
Tumor Microenvironment Immunotherapy
Immunotherapy is moving toward remodeling the tumor ecosystem rather than targeting T cells alone. Macrophage-directed mRNA lipid nanoparticles, CXCL9-associated inflammation and mEGFR-targeted photoimmunotherapy address suppressive myeloid and stromal barriers. Glioma studies emphasize distal B-cell responses in tumor-draining lymph nodes as a requirement for efficacy. The shared direction is coordinated activation of myeloid, B-cell and cytotoxic lymphocyte compartments, although the most effective combinations remain unsettled.
3 papers · 15.8%
CTLA-4-associated immune regulation is not uniformly suppressive but can support protective or antitumor inflammation
Latent pulmonary Cryptococcus neoformans infection in mice and immune checkpoint inhibitor-induced inflammatory arthritis show that CTLA-4-associated regulatory programs do not invariably represent failed immunity. During latent cryptococcosis, CTLA-4 expression occurs within heterogeneous CD4 T-cell responses that include protective Th1-like activity, and CTLA-4-regulated responses contribute to fungal control; in checkpoint inhibitor–associated arthritis, blockade is accompanied by atypical regulatory T cells with reduced suppressive capacity and a Th17-like proinflammatory phenotype, whose abundance correlates with more severe arthritis but improved cancer outcomes. Together, these findings replace a uniformly inhibitory interpretation with a context-dependent one in which CTLA-4-related regulation can participate in protective host defense or beneficial antitumor inflammation 42484324Jul 42383349Jul.
CTLA-4 blockade can control glioma through a distal antibody-producing B-cell response
Glioma in mice provides a role for CTLA-4 blockade outside the set’s predominant T-cell-centered mechanisms. Anti-CTLA-4 treatment enhanced T follicular helper-cell expansion in tumor-draining deep cervical lymph nodes, drove germinal-center B-cell maturation and IgG class switching, and generated glioma-reactive antibodies; antibody-secreting cells were required for therapeutic benefit, while the resulting IgG accumulated in tumors and promoted glioma-cell phagocytosis. CTLA-4 blockade therefore functions here not only by releasing antitumor T-cell activity but also by initiating a distal humoral response that is necessary for tumor control 42430444Jul.
Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4)
Gene: CTLA4 | Wikidata ID: Q2907609 | Category: Gene
Papers
The 19 papers from the last 6 months that study Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
Checkpoint Autoimmunity and Cancer (6)
- Cytokines and chemokines in plasma as markers reflecting immunophenotype of head and neck squamous cell carcinoma. Human cell · 2 Sept 2026 PMID 42684559
- Iparomlimab and tuvonralimab in previously treated patients with cervical cancer. Cell reports. Medicine · 4 Aug 2026 PMID 42551432
- Immune checkpoint inhibitor-induced myasthenia gravis and myocarditis: a fatal immune-related adverse event. Immunologic research · 1 Jul 2026 PMID 42384108
- Checkpoint inhibitors create rogue regulatory T cells. The Journal of clinical investigation · 1 Jul 2026 PMID 42383349
- Engineering and Improving Anti-CTLA-4 Checkpoint Inhibitors. Clinical cancer research : an official journal of the American Association for Cancer Research · 8 Jun 2026 PMID 42258254
- Loss of the autoimmune risk gene TREX1 reveals a convergence of mechanisms promoting immune tolerance loss and antitumor immunity. Science advances · 6 May 2026 PMID 42090506
T-Cell-Directed Cancer Immunotherapy (6)
- Identification of a circulating miR-6838-5p/miR-195-5p signature in invasive ductal breast carcinoma. Molecular biology reports · 16 Sept 2026 PMID 42747628
- Anti-CTLA-4 antibody potentiates the antitumor effect of armed oncolytic virus OVM18 via enhancing intratumoral IL-18R1+CD8+ T cells. Journal for immunotherapy of cancer · 7 Sept 2026 PMID 42705862
- In Situ Vaccination, Low-Dose Targeted Radionuclide Therapy, and Immune Checkpoint Inhibition Eradicate Poorly Immunogenic Metastatic Tumors in Murine Cancer Models. Cancer immunology research · 8 Jul 2026 PMID 42418729
- Immune Checkpoint Blockade Augments Lymphodepleting Chemotherapy-Induced Antitumor Immunity by Expanding Effector CD8+ T-cell Clones. Cancer research · 22 Jun 2026 PMID 42329854
- Transcriptomic profiling identifies immunotherapy-responsive phenotypes in microsatellite-stable metastatic colorectal cancer. Oncogene · 15 Jun 2026 PMID 42298180
- Integrating network pharmacology with ex-vivo analysis to assess the effect of IL-2 in halting breast cancer: involvement of Treg/CTLA-4/Blimp-1/caspase-3. Scientific reports · 26 May 2026 PMID 42192107
Checkpoint Immune Regulation (4)
- Paradoxical Th1 activation and CTLA-4 regulation is beneficial during latent cryptococcosis. mBio · 22 Jul 2026 PMID 42484324
- Repurposed ethoxzolamide reprograms antitumor immunity through β-TrCP-dependent PD-L1 ubiquitination. Cell reports. Medicine · 13 Jul 2026 PMID 42442361
- Vasoactive intestinal peptide associated 8-gene signature with prognostic and immune associations in melanoma. Medicine · 30 May 2026 PMID 42216340
- Gene-level gut microbiome signatures as predictive biomarkers for response to immune checkpoint inhibitors across multiple cancer types. Gut microbes · 24 Apr 2026 PMID 42026803
Tumor Microenvironment Immunotherapy (3)
- Targeting tumor-associated macrophages using mRNA lipid nanoparticles for cytotoxic T lymphocyte-mediated cancer immunotherapy. Science advances · 11 Sept 2026 PMID 42726873
- The efficacy of immunotherapy in glioma requires distal B cell responses in tumor-draining lymph nodes. Science immunology · 10 Jul 2026 PMID 42430444
- Understanding tumor microenvironment dynamics and immune checkpoint inhibitor efficacy following mEGFR-targeted near-infrared photoimmunotherapy. Cancer letters · 17 Apr 2026 PMID 41997285
By study type
Clinical trials (1)
- Iparomlimab and tuvonralimab in previously treated patients with cervical cancer. Cell reports. Medicine · 4 Aug 2026 PMID 42551432
Observational studies and case reports (2)
- Identification of a circulating miR-6838-5p/miR-195-5p signature in invasive ductal breast carcinoma. Molecular biology reports · 16 Sept 2026 PMID 42747628
- Immune checkpoint inhibitor-induced myasthenia gravis and myocarditis: a fatal immune-related adverse event. Immunologic research · 1 Jul 2026 PMID 42384108
Human data, design not indexed (5)
- Cytokines and chemokines in plasma as markers reflecting immunophenotype of head and neck squamous cell carcinoma. Human cell · 2 Sept 2026 PMID 42684559
- Transcriptomic profiling identifies immunotherapy-responsive phenotypes in microsatellite-stable metastatic colorectal cancer. Oncogene · 15 Jun 2026 PMID 42298180
- Vasoactive intestinal peptide associated 8-gene signature with prognostic and immune associations in melanoma. Medicine · 30 May 2026 PMID 42216340
- Integrating network pharmacology with ex-vivo analysis to assess the effect of IL-2 in halting breast cancer: involvement of Treg/CTLA-4/Blimp-1/caspase-3. Scientific reports · 26 May 2026 PMID 42192107
- Gene-level gut microbiome signatures as predictive biomarkers for response to immune checkpoint inhibitors across multiple cancer types. Gut microbes · 24 Apr 2026 PMID 42026803
Preclinical: animal, cell and lab studies (11)
- Targeting tumor-associated macrophages using mRNA lipid nanoparticles for cytotoxic T lymphocyte-mediated cancer immunotherapy. Science advances · 11 Sept 2026 PMID 42726873
- Anti-CTLA-4 antibody potentiates the antitumor effect of armed oncolytic virus OVM18 via enhancing intratumoral IL-18R1+CD8+ T cells. Journal for immunotherapy of cancer · 7 Sept 2026 PMID 42705862
- Paradoxical Th1 activation and CTLA-4 regulation is beneficial during latent cryptococcosis. mBio · 22 Jul 2026 PMID 42484324
- Repurposed ethoxzolamide reprograms antitumor immunity through β-TrCP-dependent PD-L1 ubiquitination. Cell reports. Medicine · 13 Jul 2026 PMID 42442361
- The efficacy of immunotherapy in glioma requires distal B cell responses in tumor-draining lymph nodes. Science immunology · 10 Jul 2026 PMID 42430444
- In Situ Vaccination, Low-Dose Targeted Radionuclide Therapy, and Immune Checkpoint Inhibition Eradicate Poorly Immunogenic Metastatic Tumors in Murine Cancer Models. Cancer immunology research · 8 Jul 2026 PMID 42418729
- Checkpoint inhibitors create rogue regulatory T cells. The Journal of clinical investigation · 1 Jul 2026 PMID 42383349
- Immune Checkpoint Blockade Augments Lymphodepleting Chemotherapy-Induced Antitumor Immunity by Expanding Effector CD8+ T-cell Clones. Cancer research · 22 Jun 2026 PMID 42329854
- Engineering and Improving Anti-CTLA-4 Checkpoint Inhibitors. Clinical cancer research : an official journal of the American Association for Cancer Research · 8 Jun 2026 PMID 42258254
- Loss of the autoimmune risk gene TREX1 reveals a convergence of mechanisms promoting immune tolerance loss and antitumor immunity. Science advances · 6 May 2026 PMID 42090506
- Understanding tumor microenvironment dynamics and immune checkpoint inhibitor efficacy following mEGFR-targeted near-infrared photoimmunotherapy. Cancer letters · 17 Apr 2026 PMID 41997285
Written from 19 PubMed abstracts, each one listed by PMID above. Published: 2026-06-15. Last written: 2026-09-18 by GPT. Corrections: 2026-09-26 by GPT. Drafted by language models from published abstracts; not medical advice.